Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

21. Gabapentin (Neurontin): risk of severe respiratory depression

Gabapentin (Neurontin): risk of severe respiratory depression Gabapentin (Neurontin): risk of severe respiratory depression - GOV.UK GOV.UK uses cookies to make the site simpler. Search Gabapentin (Neurontin): risk of severe respiratory depression Gabapentin has been associated with a rare risk of severe respiratory depression even without concomitant opioid medicines. Patients with compromised respiratory function, respiratory or neurological disease, renal impairment, concomitant use (...) of central nervous system (CNS) depressants, and elderly people might be at higher risk of experiencing severe respiratory depression. Dose adjustments might be necessary in these patients. Published 26 October 2017 From: Therapeutic area: , Contents Advice for healthcare professionals: be aware of the risk of CNS depression, including severe respiratory depression, with gabapentin consider whether dose adjustments might be necessary in patients at higher risk of respiratory depression, including elderly

2017 MHRA Drug Safety Update

22. Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial Full Text available with Trip Pro

Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial Neuropathic pain is one of the most common complaints of neurologic clinics. Neuropathic pain is common and important and has inappropriate complications, and despite their importance, there is no effective treatment for them.Because of the importance of neuropathic pain and safe and effective treatment, in this study, we determined the effect of topiramate (...) versus gabapentin in patients with neuropathic pain.In this randomized clinical trial, 30 patients with pain attributed to neuropathy who had at least one month of neuropathic pain in one area, were randomized to receive either gabapentin, titrated from 300 mg/day to a maximum of 900 mg/day or topiramate, titrated from 50 mg/day to a maximum of 100 mg/day after a 4-week period in the neurology clinic of Imam Khomeini Hospital of Urmia city, Iran in 2015. Complication, drug tolerance rate and pain

2017 Electronic physician Controlled trial quality: uncertain

23. Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines

Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines | CADTH.ca Find the information you need Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines Published on: October 19, 2017 Project Number: RB1146-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What (...) is the clinical evidence for the potential misuse or abuse of gabapentin? What are the harms associated with the potential misuse or abuse of gabapentin? What are the evidence-based guidelines regarding managing patients abusing gabapentin? Key Message Three systematic reviews and three non-randomized studies were identified regarding the potential abuse and misuse of gabapentin. Tags street drugs, substance abuse detection, substance abuse treatment centers, addiction, gabapentin Files Rapid Response Summary

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

24. Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial Full Text available with Trip Pro

Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial Postoperative pain and opioid use are associated with postoperative delirium. We designed a single-center, randomized, placebo-controlled, parallel-arm, double-blinded trial to determine whether perioperative administration of gabapentin reduced postoperative delirium after noncardiac surgery.Patients were randomly assigned to receive placebo (N = 347) or gabapentin 900 mg (N (...) = 350) administered preoperatively and for the first 3 postoperative days. The primary outcome was postoperative delirium as measured by the Confusion Assessment Method. Secondary outcomes were postoperative pain, opioid use, and length of hospital stay.Data for 697 patients were included, with a mean ± SD age of 72 ± 6 yr. The overall incidence of postoperative delirium in any of the first 3 days was 22.4% (24.0% in the gabapentin and 20.8% in the placebo groups; the difference was 3.20%; 95% CI

2017 EvidenceUpdates

25. Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness

Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Published on: July 31, 2017 (...) Project Number: RB1124-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of pre-operative administration of gabapentin to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of celecoxib to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of acetaminophen to reduce post

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

27. Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes Full Text available with Trip Pro

Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin.The design of this comparative efficacy and safety study of pregabalin and gabapentin as adjunctive treatment in adults with refractory partial-onset seizures was randomized (...) , flexible dose, double blind, and parallel group. The study included a 6-week baseline and a 21-week treatment phase. The primary endpoint was the percentage change from baseline in 28-day seizure rate to the treatment phase.A total of 484 patients were randomized to pregabalin (n = 242) or gabapentin (n = 242). Of these, 359 patients (187 pregabalin, 172 gabapentin) completed the treatment phase. The observed median and mean in percentage change from baseline was -58.65 and -47.7 (SD 48.3

2016 EvidenceUpdates Controlled trial quality: predicted high

28. Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness

Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness Published on: January 22, 2016 Project Number: RC0750-000 Product Line: Research Type: Drug Report Type (...) : Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain? Key Message There is limited evidence for the use of gabapentin for the treatment of HIV-associated neuropathy. One relevant RCT, included in a systematic review, and one non-randomized study were identified. The studies suggest that gabapentin may improve pain and related sleep disturbances caused by HIV-associated sensory neuropathy

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

29. Neuropathic pain - drug treatment: Gabapentin

Neuropathic pain - drug treatment: Gabapentin Gabapentin | Prescribing information | Neuropathic pain - drug treatment | CKS | NICE Search CKS… Menu Gabapentin Neuropathic pain - drug treatment: Gabapentin Last revised in February 2020 Gabapentin Is gabapentin licensed for neuropathic pain? Gabapentin is licensed for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and postherpetic neuralgia in adults [ ]. However, the National Institute for Health and Care (...) Excellence (NICE) recommends gabapentin as a first-line treatment option for adults with all neuropathic pain (except trigeminal neuralgia) [ ]. Dose and titration Fast titration (usually suitable for otherwise healthy younger adults). Initially, 300 mg once a day on day 1, then 300 mg twice a day on day 2, then 300 mg three times a day on day 3. Alternatively, start with 300 mg three times a day on day 1, then increase according to response in steps of 300 mg (in three divided doses) every 2–3 days up

2016 NICE Clinical Knowledge Summaries

30. Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness

Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness Published on: November 25, 2015 Project Number: RA0817-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical (...) effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain? Key Message One systematic review, one randomized controlled trial, and one non-randomized study were identified regarding the clinical effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain. Tags hiv, human immunodeficiency virus, human immunodeficiency viruses, neuralgia, pain management, hiv/aids, other miscellaneous topics, Neurontin, human immuno-deficiency virus, human immuno-deficiency viruses

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

31. Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014

Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 | CADTH.ca Find the information you need Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 (...) , as well as place a significant burden on our health, social services, and public safety systems.” 1 The purpose of this Environmental Scan is to provide an overview of policies, practices, and initiatives which the publicly funded drug programs, colleges of physicians and surgeons, and colleges of pharmacy are implementing across Canada to address the misuse, abuse, and diversion of prescription narcotics (opioids), benzodiazepines, stimulants, and gabapentin. This information may assist drug policy

2015 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

32. Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. Full Text available with Trip Pro

Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. To evaluate whether an epidural steroid injection or gabapentin is a better treatment for lumbosacral radiculopathy.A multicenter randomized study conducted between 2011 and 2014. Computer generated randomization was stratified by site. Patients and evaluating physicians were blinded to treatment outcomes.Eight military, Veterans Administration (...) global perceived effect. All patients had one month follow-up visits; patients whose condition improved remained blinded for their three month visit.There were no significant differences for the primary outcome measure at one month (mean pain score 3.3 (SD 2.6) and mean change from baseline -2.2 (SD 2.4) in epidural steroid injection group versus 3.7 (SD 2.6) and -1.7 (SD 2.6) in gabapentin group; adjusted difference 0.4, 95% confidence interval -0.3 to 1.2; P=0.25) and three months (mean pain score

2015 BMJ Controlled trial quality: predicted high

33. Gabapentin for Adults with Neuropathic Pain

Gabapentin for Adults with Neuropathic Pain Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Efficacy

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

34. Randomized controlled trial of gabapentin as an adjunct to perioperative analgesia in total hip arthroplasty patients Full Text available with Trip Pro

Randomized controlled trial of gabapentin as an adjunct to perioperative analgesia in total hip arthroplasty patients Gabapentin was investigated as a single-dose adjunct to morphine for postoperative pain management. The primary objective was to determine if gabapentin given preoperatively and for two days postoperatively as part of multimodal analgesia would decrease postoperative morphine consumption in patients undergoing primary total hip arthroplasty (THA).The study group included 102 (...) patients aged 19-90 years who were undergoing primary THA in a single joint with no contraindications to the study medications, no chronic pain syndrome, and no chronic opioid use. Intervention group patients (n = 48) received gabapentin 600 mg po preoperatively and 200 mg postoperatively on the day of surgery. They were continued on gabapentin at 200 mg three times daily for two days. Control group patients (n = 54) received placebo in a similar fashion. Preoperatively, all patients were given 30 mg

2015 EvidenceUpdates Controlled trial quality: predicted high

35. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

2014 Prescrire

36. Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity

Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity UTCAT2762, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity Clinical Question In a patient with fixed orthodontic bands and nighttime parafunctional habits, is gabapentin as effective and safe as an oral appliance (...) in reducing levels of nighttime masticatory EMG activity? Clinical Bottom Line Gabapentin (200 or 300 mg at bedtime) is a good treatment option for reducing nighttime masticatory EMG activity when an occlusal appliance cannot be used; it also has a good safety profile. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Madani/2012 20 patients (stabilization splint group [n = 10] and gabapentin group [n = 10

2014 UTHSCSA Dental School CAT Library

37. Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?

Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do venlafaxine and gabapentin control hot flashes in women with a history of breast (...) cancer? View/ Open Date 2012-12 Format Metadata Abstract Venlafaxine reduces hot flashes more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes). Gabapentin also reduces hot flashes more than placebo (SOR: B, a single RCT); adverse effects include dizziness and somnolence (SOR: C, standard reference). After having tried both medications, women

2014 Clinical Inquiries

38. Gabapentin

Gabapentin USE OF GABAPENTIN IN PREGNANCY 0344 892 0909 USE OF GABAPENTIN IN PREGNANCY (Date of issue: November 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Gabapentin is an antiepileptic drug indicated as monotherapy (...) or adjunctive therapy in the treatment of partial seizures with or without secondary generalisation, and for the treatment of peripheral neuropathic pain. The available data concerning gabapentin exposure in pregnancy consist of relatively small prospective cohort studies (n=8) and ten case reports/series. Most data relates to gabapentin use in pregnancy for the treatment of maternal epilepsy. A few case reports/series describe use of gabapentin in the treatment of neuropathic pain or hyperemesis gravidarum

2014 UK Teratology Information Service

39. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014

Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Environmental Scans; issue 45. 2014 Authors' conclusions The survey of Canada's publicly funded drug plans, colleges of physicians and surgeons, and colleges of pharmacists shows that jurisdictions have established multiple avenues to address the issue

2014 Health Technology Assessment (HTA) Database.

40. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines

Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) CADTH. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Indirect evidence suggests similar short-term pain relief with gabapentin compared with pregabalin, tricyclic antidepressants and serotonin norepinephrine reuptake inhibitors in patients with painful diabetic neuropathy, postherpetic neuralgia and fibromyalgia. There is lower quality

2014 Health Technology Assessment (HTA) Database.